Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 04, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details specific changes in share interests held by the GlaxoSmithKline Employee Trust ("GSK Trust") and related transactions:
- March 31, 2006: The GSK Trust transferred 17,721 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- March 31, 2006: The GSK Trust transferred an additional 14,800 Ordinary Shares to participants in the same plan.
- April 03, 2006: Following a reconciliation of holdings, the Company was advised of a net disposal of 469,815 Ordinary Shares by the GSK Trust.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) are interested in shares held in the GSK Trust as potential beneficiaries, similar to other employees. The notification complies with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Checklist
- Verify the total number of Ordinary Shares transferred to employee option plan participants on March 31, 2006.
- Confirm the details of the net disposal of 469,815 Ordinary Shares by the GSK Trust reconciled on April 03, 2006.
- Review the specific interests of Directors Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop in the GSK Trust holdings.